Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coherus BioSciences

CHRS vs. ILMN: Which Stock Is the Better Value Option?

CHRS or ILMN: Which Is the Better Value Stock Right Now?

Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.

Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic

ABIOMED

Chipotle

Fortinet

MSCI

ResMed

Rollins

Teradyne

Under Armour

Zebra Technologies

The market itself is sitting at lofty valuations, but several S&P 500 stocks are extremely overheated. Consider giving these 10 picks a little time to cool off.

10 S&P 500 Stocks to Consider … At Much Lower Prices

Coherent Corp

Even as markets took a pause, there's still plenty of action in individual stock names.

Why These 2 Hot Nasdaq Stocks Are Soaring Friday

Illumina stock rocketed to a record Friday after the company boosted its first quarter outlook on the growing need for DNA sequencing to surveil Covid-19 mutations and vaccines. The post Illumina Stock: Covid, Bioterrorism And Grail Just Sent It To A Record appeared first on Investor's Business Daily.

Illumina Stock: Covid, Bioterrorism And Grail Just Sent It To A Record

The genomic sequencing pioneer reported great fourth-quarter results.

Why Illumina Stock Is Skyrocketing Today

Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.

Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline

Illumina's (ILMN) CEO Francis deSouza on Q4 2020 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Q4&FY 2020 Earnings Release

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020

Illumina (NASDAQ:ILMN) will be releasing its next round of earnings this Thursday, February 11. For all of the relevant information, here is your guide for Thursday's Q4 earnings announcement.

A Preview Of Illumina's Earnings

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--SVB Leerink & Cowen Annual Global Healthcare Conferences Webcasting

Illumina to Webcast Upcoming Investor Conference Presentations

Illumina (ILMN) is likely to have gained during the fourth quarter from the robust performance of sequencing consumable segment.

Illumina (ILMN) to Report Q4 Earnings: What's in the Offing?

SAN DIEGO--(BUSINESS WIRE)--Illumina has selected nine new genomics companies for the second global funding cycle of Illumina Accelerator.

Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle

The genomics leader got a boost from identifying new COVID variants, and won a patent lawsuit.

Why Shares of Illumina Rose 15.3% in January

Dynavax Technologies

Exelixis

I-Mab

Eli Lilly

Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1

SAN DIEGO--(BUSINESS WIRE)--Illumina announced support for national pilot study in Belgium to evaluate impact of comprehensive genomic profiling for late stage cancer.

Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium

Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.

Illumina (ILMN) New Collaboration to Aid Genomics Startups

Fulgent Genetics

Analysts' pessimism about these stocks appears to be off-base.

2 Stocks That Wall Street Hates but You'll Probably Like

SAN DIEGO--(BUSINESS WIRE)--Illumina and Sequoia Capital will collaborate to build an ecosystem for life science startup companies advancing breakthrough applications in genomics

Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China

Illumina, best known for its genetic variation and biological function systems, has gained 9.5% over the last 5 trading days, after a UK court announced a judgment in Illumina's favor in a patent infringement suit filed against the BGI Companies.

Should You Buy Illumina Stock After A 10% Move In 5 Days?

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Q4&FY 2020 Earnings Date Announcement

Illumina to Announce Fourth Quarter & Full Year 2020 Financial Results on Thursday, February 11, 2021

Illumina (ILMN) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Illumina (ILMN) is in Overbought Territory: What's Next?

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infringement suit filed against the BGI Companies, MGI Tech Co. Ltd; Latvia MGI SIA; MGI International Sales Co., Ltd; and BGI Complete Genomics Hong Kong Co., Ltd. The Court found that four of the five asserted patents were valid and infringed by BGI. The Court ruled that BGI's StandardMPS and CoolMPS systems in

Illumina Wins Patent Infringement Suit against BGI in the UK

Amgen

Trillium Therapeutics

Buy these three biotech stocks before they take off.

3 Top Biotech Picks for January

Myriad Genetics

Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.

News for Illumina Stock (ILMN)